Peptide Containing Patents (Class 514/773)
-
Publication number: 20090170959Abstract: Compositions and methods for delivering bioactive agents, such as vitamins, hormones, nutrients and drugs, by stabilizing and or solubilizing these agents in a polymer matrix. The carrier polymers can be used in drug delivery and are useful for delivery of small molecules.Type: ApplicationFiled: June 18, 2008Publication date: July 2, 2009Inventors: Jin Kim Montclare, Man Xia Lee, Jennifer Haghpanah
-
Publication number: 20090157017Abstract: Provided is a flowable bioresorbable tissue dressing comprising a gas-forming porogen and a gel or gel-forming solution. Also provided is kits for preparing the above-described tissue dressing. Further provided are methods of treating a tissue site of a mammal with the above dressing. Also provided is a reduced pressure delivery system for applying a reduced pressure tissue treatment to a tissue site.Type: ApplicationFiled: December 31, 2008Publication date: June 18, 2009Inventor: Archel Ambrosio
-
Publication number: 20090155346Abstract: The invention discloses a method for preparing a powder from an aqueous liquid which comprises colloidal particles. The method is based on the use of dense-phase extraction media, i.e. near-critical or supercritical fluids. The powder obtained through the method can be reconstituted with an appropriate aqueous liquid to yield a colloidal dispersion. The method is particularly useful for drying and stabilising aqueous colloidal dispersions comprising an active compound, such as a drug substance.Type: ApplicationFiled: December 8, 2006Publication date: June 18, 2009Applicants: FEYECON DEVELOPMENT & IMPLEMENTATION B.V.Inventors: Gerhard Winter, Michael Wiggenhorn, Hubert Clemens Pellikaan
-
Publication number: 20090156691Abstract: A cell cultivation carrier implantable in vivo having independent pore with opening of 100 ?m-1000 ?m on the surface thereof produced by neutralization•gellation of collagen acidic solution, said collagen acidic solution is preliminary prepared by passing through a filter of 10 ?m or less pore size by 5-20 mg/mL concentration. Especially, a cell cultivation carrier implantable in vivo having sufficiently self-organized accumulation shape•structure obtained by carrying out said neutralization under directionally supplying of alkali.Type: ApplicationFiled: August 18, 2005Publication date: June 18, 2009Applicant: KOKEN CO., LTD.Inventors: Yu Aso, Makiko Kono
-
Publication number: 20090155363Abstract: The present invention relates to methods that facilitate the oral administration of active drugs to a patient. Specifically, the methods of the present invention may utilize compositions comprising an active drug and a gelling agent that provides an easily consumable gel dosage form and the active drug is homogenously mixed within the gel.Type: ApplicationFiled: December 14, 2007Publication date: June 18, 2009Inventor: Todd Maibach
-
Publication number: 20090156692Abstract: The invention relates to the use of oilgomers and polymers capable of rendering insoluble drugs soluble, protecting unstable drugs, and facilitating the delivery of drugs to their site of action. This invention further relates to processes for the preparation of such oilgomers and polymers, and to compositions containing them.Type: ApplicationFiled: December 18, 2008Publication date: June 18, 2009Inventors: David S. Soane, Daniel J. Suich
-
Publication number: 20090142266Abstract: Use of a peptide vector for intracellular addressing of a substance of interest, said vector essentially comprising a peptide which is derived from maurocalcine corresponding to the following sequence (I): Z-X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17-X18-X19-X20-X21-X22-X23-X24-X25-X26-Z?, wherein X1 and X26 each represent a cysteine, X2 to X25 each represent an amino acid or are absent, X7, X10, X11, X12, X13, X14, X15, and X16 are always present, and X10, X11, X13 and X14 each represent a lysin or an arginine, and Z and/or Z? are absent or each represent a sequence of 1-35 amino acids, with the exception of the peptide having SEQ ID NO: 1 in the list of sequences contained in the annex.Type: ApplicationFiled: November 14, 2005Publication date: June 4, 2009Inventors: Michel Ronjat, Michel De Waard
-
Publication number: 20090143487Abstract: This invention is directed to the application of a previously unknown property of nanomaterials—its ability to enhance protein activity and stability at high temperatures, in organic solvents, and in polymer composites. Nanomaterials such as single-walled carbon nanotubes (SWNTs) can significantly enhance enzyme function and stability in strongly denaturing environments. Experimental results and theoretical analysis reveal that the enhancement in stability is a result of the curvature of these nanoscale materials, which suppresses unfavorable protein-protein interactions. The enhanced stability is also exploited in the preparation of highly stable and active nanocomposite films that resist nonspecific protein absorption, i.e., inhibit fouling of the films. The protein-nanoparticles conjugates represent a new generation of highly selective, active, and stable catalytic materials.Type: ApplicationFiled: September 7, 2005Publication date: June 4, 2009Inventors: Jonathan S. Dordick, Ravindra S. Kane, Prashanth Asuri, Sandeep S. Karajanagi
-
Publication number: 20090143488Abstract: The invention relates to compositions and methods of using the flavor active peptides, Lys-Ile-His-Pro-Phe (SEQ ID NO:1), Gly-Pro-Phe-Pro-Ile (SEQ ID NO:2), and Lys-Lys-Tyr-Lys-Val-Pro-Gln (SEQ ID NO:3), to impart a bitter, salt, dairy or umami flavor to food or pharmaceutical products. In particular embodiments, the Lys-Lys-Tyr-Lys-Val-Pro-Gln (SEQ ID NO:3) peptide further imparts a vegetable, brothy, or bready flavor.Type: ApplicationFiled: December 3, 2007Publication date: June 4, 2009Inventors: Laurence Trinnaman, Zhihua Liu, Linda Ann Psota-Kelty, Zhen Chen
-
Publication number: 20090143295Abstract: Peptide-based antiacne reagents, formed by coupling a skin-binding peptide with an antiacne agent, are described. The skin-binding peptide portion of the peptide-based antiacne reagent binds strongly to the skin, thus keeping the antiacne agent coupled to the skin for a long lasting effect. Skin care compositions comprising the peptide-based antiacne reagents are also provided as well as a method of treating or preventing skin acne.Type: ApplicationFiled: November 19, 2008Publication date: June 4, 2009Applicant: E. I. DU PONT DE NEMOURS AND COMPANYInventors: JOHN P. O'BRIEN, Hong Wang, Antoinette E. Wilkins
-
Publication number: 20090142403Abstract: An organ regeneration device adapted to be used by placing it into a defective portion of an organ to regenerate the organ is provided. The organ regeneration device has a base body having a shape corresponding to a shape of the defective portion of the organ. The organ regeneration device also has particles carried on the base body, wherein the particles are composed of a different material from that of the base body. The organ regeneration device also has a growth-related substance contained in the organ regeneration device for growth and differentiation of cells around the defective portion. The growth-related substance contains an angiogenesis factor. Further, the growth-related substance contains nucleic acid containing a base sequence coding for amino-acid sequence of a growth factor different from the angiogenesis factor. Furthermore, the nucleic acid is introduced into a host cell.Type: ApplicationFiled: November 28, 2008Publication date: June 4, 2009Applicants: HOYA CORPORATIONInventors: Ichiro ONO, Yoshikiyo AKASAKA, Takehiko NAKAJIMA
-
Publication number: 20090143322Abstract: Compositions incorporating small interfering ribonucleic acid (siRNA) and certain lipid-conjugated polyamide compound-based delivery vehicles that are particularly useful in the delivery siRNA and other polynucleotides to cells. Also, methods of making and using the compositions.Type: ApplicationFiled: March 21, 2008Publication date: June 4, 2009Applicant: CHIRON CORPORATIONInventors: Timothy S. Burkoth, Anne B. Jefferson, Christoph Reinhard, Ronald N. Zuckermann
-
Publication number: 20090143486Abstract: Described are charge reversible polymers, peptides and their resulting colloidal particles, comprising polymers and peptides having primary and secondary amines that are protected as easily hydrolysable amides. The amides are charge-reversible such that at neutral pH they are negatively charged but become positively charged at pH less than 6 and thus are relatively stable at neutral pH but quickly hydrolyze at pH below 6. Incorporating a drug in a micelle or a polymer comprised of the charge-reversible polymers or peptides provides a drug carrier for delivering the drug preferentially to the solid tumor or other targeted cells.Type: ApplicationFiled: September 30, 2008Publication date: June 4, 2009Inventors: Youqing Shen, Peisheng Xu
-
Publication number: 20090136585Abstract: Surface-modified polymeric nanoparticles (NPs), compositions for making them, and their use in drug delivery are disclosed.Type: ApplicationFiled: August 1, 2008Publication date: May 28, 2009Inventors: Vinod Labhasetwar, Jaspreet K. Vasir
-
Publication number: 20090131476Abstract: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.Type: ApplicationFiled: September 26, 2008Publication date: May 21, 2009Applicant: SHIRE LLCInventors: Travis Mickle, Suma Krishnan, Barney Bishop, Christopher Lauderback, James Scott Moncrief, Robert Oberlender, Thomas Piccariello, Bernhard J. Paul, Christopher A. Verbicky
-
Publication number: 20090124708Abstract: Implant compositions are disclosed consisting of a biocompatible carrier medium such as a saline or dextran solution and particles of collagenous material dispersed therein. The collagenous material is derived from tissue which has been milled to provide fragments of collagen fibres which preserve the architecture of the original fibres and their molecular structure. The collagenous material is also substantially free of non-fibrous tissue proteins, glycoproteins, cellular elements and lipids or lipid residues, and is non-cytotoxic. By suitable choice of particle size and concentration, the composition may be presented in injectable form or as a paste. The compositions are suitable for application in cosmetic and reconstruction surgery.Type: ApplicationFiled: December 19, 2008Publication date: May 14, 2009Inventors: Roy Oliver, Roy Grant
-
Publication number: 20090110753Abstract: The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the enzyme Thimet oligopeptidase, or TOP. Also disclosed are methods of designing prodrugs by utilizing TOP-cleavable sequences within the conjugate and methods of treating patients with prodrugs of the invention.Type: ApplicationFiled: August 14, 2008Publication date: April 30, 2009Applicant: MEDAREX, INC.Inventors: Vincent Dubois, Anne Marie Fernandez, Sanjeev Gangwar, Evan Lewis, Thomas J. Lobl, Matthew H. Nieder, Lesley B. Pickford, Andre Trouet, Geoffrey T. Yarranton
-
Publication number: 20090104291Abstract: It is an object of the present invention to provide a nanoparticle which comprises a blood circulation promoter and a biodegradable polymer, which is safe and excellent in terms of dispersion stability and has high transparency and good absorbability due to its small particle size. The present invention provides a water-dispersible nanoparticle which comprises a blood circulation promoter and a biodegradable polymer.Type: ApplicationFiled: October 16, 2008Publication date: April 23, 2009Applicant: FUJIFILM CorporationInventor: Katsuhiko KANAZAWA
-
Publication number: 20090098176Abstract: Described herein are implantable medical devices comprising a biocompatible polymer comprising a triggerable bioadhesive property that allows the device to adhere to body tissue. The triggerable bioadhesive property of the polymer can be triggered or activated by exposure to a stimulus. Also, the present invention pertains to methods of making an implantable medical device comprising a biocompatible polymer comprising a triggerable bioadhesive property that allows the device to adhere to body tissue.Type: ApplicationFiled: September 10, 2008Publication date: April 16, 2009Applicant: Boston Scientific Scimed, Inc.Inventors: Michael N. Helmus, Yixin Xu, Barron W. Tenney, Paul L. Valint, Shrirang V. Ranade
-
Publication number: 20090093551Abstract: The present invention provides particle conjugates for drug delivery. Such conjugates comprise one or more heatable surfaces, one or more thermally-responsive linkers, and one or more agents to be delivered. In some embodiments, conjugates and populations of conjugates can be used to treat and/or diagnose a disease, disorder, and/or condition. The present invention provides methods for producing and/or using thermally-responsive conjugates.Type: ApplicationFiled: December 7, 2007Publication date: April 9, 2009Inventors: Sangeeta N. Bhatia, Austin M. Derfus, Geoffrey von Maltzahn
-
Publication number: 20090092548Abstract: The present invention relates to peptides which home to cells, e.g. heart cells, with high selectivity and which can be useful in the form of compositions. Such compositions can be used, e.g., for selectively targeting a systemically administered therapeutic agent or imaging agent to a cell or tissue in a subject. The present invention further relates to methods of using the compositions for imaging, e.g. PET imaging, and targeting cells, e.g. for delivering a therapeutic agent to one or more target cells in a subject.Type: ApplicationFiled: September 8, 2008Publication date: April 9, 2009Inventors: Katherine Ferrara, Hua Zhang, Jiro Kusunose
-
Publication number: 20090092663Abstract: The present invention relates to targeted delivery systems for delivering therapeutic agents to tumor. The invention further relates to methods of delivering a therapeutic agent to a tumor for the prevention and treatment of cancer by killing tumor cells and tumor-associated endothelial cells. In particular, the present invention provides a tumor-targeted drug delivery system comprising a NGR-containing molecule linked to a delivery vehicle encapsulating a therapeutic agent, preferably a drug, such as a cytotoxic agent or a chemotherapeutic agent. Specifically, the delivery systems of the present invention are capable of delivering an increased amount of therapeutic agent to a tumor as compared to other delivery systems.Type: ApplicationFiled: August 29, 2008Publication date: April 9, 2009Applicants: G. Gaslini Children's Hospital, Fondazione Centro San Raffaele Del Monte Tabor, The Governors of the University of AlbertaInventors: Mirco Ponzoni, Angelo Corti, Theresa M. Allen
-
Publication number: 20090087484Abstract: A formulation and dosage form for enhancing the bioavailability of orally administered hydrophilic macromolecules includes a permeation enhancer, a hydrophilic macromolecule, and a carrier such as a nonionic surfactant that exhibits in-situ gelling properties. The formulation is delivered within the GI tract as a liquid having at least some affinity for the surface of the GI mucosal membrane. Once released, it is believed that the liquid formulation spreads across one or more areas of the surface of the GI mucosal membrane, where the carrier of the formulation then transitions into a bioadhesive gel in-situ. As a bioadhesive gel, the formulation presents the hydrophilic macromolecule and the permeation enhancer at the surface of the GI mucosal membrane at concentrations sufficient to increase absorption of the hydrophilic macromolecule through the GI mucosal membrane over a period of time.Type: ApplicationFiled: September 28, 2007Publication date: April 2, 2009Applicant: ALZA CORPORATIONInventors: Liang C. DONG, Patrick S. L. WONG, Vu A. NGUYEN, Si-Hong Alicia Yum, Anthony C. CHAO, Peter E. Daddona
-
Publication number: 20090076176Abstract: The product of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide having a plasmin peptide substrate of 2-4 amino acids and mono- or di-peptide linkage, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by plasmin. Also disclosed are methods of making and using the prodrug compounds.Type: ApplicationFiled: June 11, 2008Publication date: March 19, 2009Applicant: MEDAREX, INC.Inventors: Andre Trouet, Vincent Dubois, Alexandre Passioukov
-
Publication number: 20090074875Abstract: The present invention is directed to nanoparticulate active agent compositions comprising lysozyme as a surface stabilizer. Also encompassed by the invention are pharmaceutical compositions comprising a nanoparticulate active agent composition of the invention and methods of making and using such nanoparticulate and pharmaceutical compositions.Type: ApplicationFiled: November 12, 2008Publication date: March 19, 2009Inventors: Christian F. Wertz, Niels P. Ryde
-
Publication number: 20090074828Abstract: The present invention generally relates to polymers and macromolecules, in particular, to polymers useful in particles such as nanoparticles. One aspect of the invention is directed to a method of developing nanoparticles with desired properties. In one set of embodiments, the method includes producing libraries of nanoparticles having highly controlled properties, which can be formed by mixing together two or more macromolecules in different ratios. One or more of the macromolecules may be a polymeric conjugate of a moiety to a biocompatible polymer. In some cases, the nanoparticle may contain a drug. Other aspects of the invention are directed to methods using nanoparticle libraries.Type: ApplicationFiled: April 4, 2008Publication date: March 19, 2009Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: Frank Alexis, Liangfang Zhang, Aleksandar F. Radovic-Moreno, Frank X. Gu, Pamela Basto, Etgar Levy-Nissenbaum, Juliana Chan, Robert S. Langer, Omid C. Farokhzad
-
Publication number: 20090068104Abstract: A homogeneous conjugate for targeting and treating diseased cells wherein the conjugate has a predetermined ratio of drug molecules to protein molecules that preferentially bind to such cells and a method for making such a conjugate. The method of making the conjugate comprises adding drug molecules to linker molecules in a manner that effectively results in one molecule of drug for each molecule of linker followed by the addition of the drug-linker combination to protein molecules in order to achieve the predetermined ratio of drug molecules to protein molecules.Type: ApplicationFiled: November 13, 2008Publication date: March 12, 2009Applicant: Faulk PharmaceuticalsInventor: W. Page FAULK
-
Patent number: 7501455Abstract: The invention is related to water-soluble products and pharmaceutical formulations in solid or liquid form mainly for parenteral use. They consist of or comprise a therapeutically active substance (having low aqueous solubility and a substantial binding affinity to plasma proteins) and a plasma protein fraction in controlled aggregation state, whereby the said active substance and the said protein fraction are bound to each other by way of non-covalent bonds. It also covers processes for the preparation of the product and pharmaceutical formulation by dissolving the water-insoluble active substance in a water-miscible, pharmaceutically acceptable solvent, combining said solution with the aqueous solution of a plasma protein fraction in controlled aggregation state whereby a true solution is obtained containing the said active substance and the said protein fraction bound together by way of non-covalent bonds.Type: GrantFiled: March 17, 2004Date of Patent: March 10, 2009Assignee: Sicor, Inc.Inventors: Lajos Hegedus, Krisztina Krempels, Krisztina Paal, Gabor Petho
-
Publication number: 20090060991Abstract: A delivery system. The delivery system includes a carrier or an active compound and a glutathione or a glutathione derivative grafted thereon. The invention also provides a compound including a moiety comprising a vitamin E derivative or a phospholipid derivative, a polyethylene glycol (PEG) or a polyethylene glycol derivative bonded thereto, and a glutathione (GSH) or a glutathione derivative bonded to the polyethylene glycol or the polyethylene glycol derivative.Type: ApplicationFiled: November 3, 2008Publication date: March 5, 2009Inventors: Ae-June WANG, Chi-Heng JIAN, Shyh-Dar LI, Yi-Fong LIN, Shih-Jr LIU
-
Publication number: 20090054536Abstract: A palatable support is intended to at least partially wrap an active substance that is initially independent of the support. The support of the invention is remarkable in that it includes, as a percentage by weight based on the total weight of the support, 3% to 50% of glucose syrup, the dextrose equivalent (DE) of the glucose syrup being in the range 5 to 60.Type: ApplicationFiled: February 5, 2007Publication date: February 26, 2009Applicant: VETINNOVInventor: Jean-Pierre Maloisel
-
Publication number: 20090053290Abstract: Transdermal delivery compositions and topical compositions for application to the skin are provided. The transdermal delivery composition includes at least two penetrants working synergistically but by disparate biochemical pathways. In one embodiment, the transdermal delivery system includes benzyl alcohol and lecithin organogel. The transdermal delivery compositions are used in a variety of topical compositions as a means of transdermally delivering and topically administering different drugs and agents, including compositions promoting collagen biosynthesis, retinoids and skin lighteners, chemical denervation agents such as BOTOX®, anti-fungal agents, anesthetics and non-steroidal anti-inflammatory drugs (NSAIDs). In addition, these topical compositions may be used in combination with non-ablative treatment modalities, such as microdermabrasion, laser-based skin remodeling and radio-frequency-based skin remodeling.Type: ApplicationFiled: March 8, 2007Publication date: February 26, 2009Inventors: Bruce J. Sand, Michael Babich, Ali Zendedel Haghighi
-
Publication number: 20090053169Abstract: The present invention relates, in part, to an oligonucleotide-core carrier comprising a carrier, and oligonucleotide groups covalently linked to the carrier. The oligonucleotide groups are capable of dissociably linking load molecules such as therapeutic agents. The oligonucleotide-core carrier may also comprise protective side chains, and targeting molecules.Type: ApplicationFiled: August 19, 2008Publication date: February 26, 2009Applicant: PharmaIN CorporationInventors: Gerardo M. Castillo, Elijah M. Bolotin, Alexei A. Bogdanov, JR., Sandra Reichstetter
-
Publication number: 20090041685Abstract: A benefit agent delivery system for use in cosmetic or cleansing products is provided comprising a polysaccharide-zein complex, a benefit agent and a plasticiser. The delivery system enhances the stability of the benefit agent whilst providing for shear-triggered release of the benefit agent on application of a product to a substrate such as human skin. Also provided is a process for the preparation of the benefit agent delivery system.Type: ApplicationFiled: March 13, 2006Publication date: February 12, 2009Inventors: Rajesh Janardan Baviskar, Mridula Kini, Ram Ramesh Pradhan, Ramesh Surianarayanan
-
Publication number: 20090041848Abstract: It is an object of the present invention to provide a skin anti-aging agent for external use which comprises highly safe protein nanoparticles having high transparency due to the small particle size and high permeability into skin. The present invention provides a skin anti-aging agent for external use, which comprises protein nanoparticles containing an active ingredient.Type: ApplicationFiled: April 1, 2008Publication date: February 12, 2009Applicant: FUJIFILM CorporationInventors: Makiko AIMI, Kazutaka Ogiwara, Takuo Amano
-
Publication number: 20090036553Abstract: A pharmaceutical composition comprising an active agent bound to a scaffold for dendritic encapsulation wherein said scaffold is covalently or non-covalently attached to a polysaccharide. More specifically, the invention is directed to active agent complexes or conjugates which utilize dendritic encapsulation alone or in combination with other delivery systems to improve and target active agent release.Type: ApplicationFiled: September 12, 2008Publication date: February 5, 2009Applicant: SHIRE LLCInventors: Thomas Piccariello, Travis Mickle, Barney Bishop
-
Publication number: 20090035389Abstract: The present invention provides targeted protein cages for the specific delivery of a variety of agents to cells and tissues and methods of use. The targeted protein cages have exterior targeting moieties and therapeutic or imaging agents which are encapsulated within the protein cages or are located on the exterior surfaces of the protein cages.Type: ApplicationFiled: February 22, 2008Publication date: February 5, 2009Applicant: SpeciGen Inc.Inventors: Brian K. Campion, Marvin I. Siegel
-
Publication number: 20090036851Abstract: A personal-care article, for receiving body exudates, having a self-assembling peptide is provided.Type: ApplicationFiled: July 20, 2007Publication date: February 5, 2009Inventor: Giovanni Carlucci
-
Publication number: 20090036354Abstract: The invention relates to a carrier for administering biologically active compounds comprising one or more C1-C4 alcohols, polyols and polymers thereof, water and one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof. The carrier may be used in administering biologically active compounds, in particular pharmaceuticals including cosmetic agents.Type: ApplicationFiled: June 16, 2006Publication date: February 5, 2009Inventors: Paul Gavin, Robert Gianello, Esra Ogru
-
Publication number: 20090011028Abstract: The present invention relates to novel pharmaceutical formulations for the release of an active principle (AP) over a sustained period of time of several days, or even several weeks. The invention relates, in a first aspect, to a liquid formulation comprising at least one active principle (AP) and an aqueous suspension based on colloïdal particles of a polymer (PO), wherein said formulation satisfies the following four conditions: (a) the polymer (PO) is a polyamino acid comprising glutamic residues, wherein some glutamic residues each carry a pendant cationic group (CG), said cationic groups being identical or different from one another, and other glutamic residues each carry a pendent hydrophobic group (GH), said hydrophobic groups (GH) being identical or different from one another, (b) the pHf value of the pH of said formulation is between 3.0 and 6.Type: ApplicationFiled: May 5, 2008Publication date: January 8, 2009Applicant: Flamel Technologies, S.A.Inventors: Frederic Checot, Cecile Bonnet-Gonnet, You-Ping Chan, Olivier Breyne, Remi Meyrueix
-
Publication number: 20090010861Abstract: The present invention relates to compositions containing (fat-soluble) active ingredients and/or colorants in a matrix based on modified plant gums, i.e. plant gums that have been submitted to hydrolysis to degrade either the protein portion and/or where appropriate, the polysaccharide, and to a process for preparing these compositions as well as to modified plant gums, whose protein part is hydrolysed up to a degree of about 30%, preferably to a degree of from about 0.05 to about 30%, and/or whose polysaccharide part is hydrolysed up to a degree of about 50%, a process for the manufacture thereof and such modified plant gums themselves. The present invention further relates to the use of the compositions of this invention for the enrichment, fortification and/or for the coloration of food, beverages, animal feed, cosmetics and pharmaceutical compositions and to such food, beverages, animal feed, cosmetics and pharmaceutical compositions themselves.Type: ApplicationFiled: November 18, 2005Publication date: January 8, 2009Inventors: Markus Beck, Bruno H. Leuenberger, Christina Rebernig-Staiger, Christian Schaefer, Gerhard Wagner
-
Publication number: 20090004278Abstract: It is an object of the present invention to provide highly safe nanoparticles made from highly biocompatible materials without the use of a surfactant or synthetic polymer. The present invention provides a protein nanoparticle which is obtained by enzymatic crosslinking during and/or after the formation of protein nanoparticle.Type: ApplicationFiled: January 30, 2007Publication date: January 1, 2009Applicant: FUJIFILM CORPORATIONInventors: Makiko Aimi, Ryoichi Nemori, Yousuke Miyashita, Hiroshi Yokoyama
-
Publication number: 20090004104Abstract: Provided herein are methods of enhancing in vivo efficacy of an active agent, comprising: administering to a subject an active agent that is coupled to a bioelastic polymer or elastin-like peptide, wherein the in vivo efficacy of the active agent is enhanced as compared to the same active agent when administered to the subject not coupled to (or not associated with) a bioelastic polymer or ELP.Type: ApplicationFiled: December 20, 2006Publication date: January 1, 2009Inventor: Ashutosh Chilkoti
-
Publication number: 20080311045Abstract: Targeted therapeutic delivery systems comprising specially designed nanocarriers for intracellular therapeutic delivery, mediated by acoustic energy, for use either in vivo or in vitro, are described. Nanocarriers comprised of substantially polymersomes, and mixtures thereof, are used to treat a variety of diseases in humans and other species, such as cancer, opthalmological, pulmonary, urinary or other pathologies. Methods for preparing the targeted therapeutic delivery systems are also embodied, which comprise processing a solution comprised of biopolymers or other species and components, with or without targeting moieties, adding said biopolymers and other compounds to a solution containing one or more therapeutic agents, stabilizing or not stabilizing said nanocarriers, adding one or more contrast agents, and resulting in a targeted therapeutic delivery system. Preferred therapeutics for use with the present invention include nucleic acids, proteins, peptides, and other therapeutic macromolecules.Type: ApplicationFiled: June 1, 2008Publication date: December 18, 2008Inventor: Charles Thomas Hardy
-
Publication number: 20080311209Abstract: The present invention is directed to topical compositions, comprising isoflavone nanoparticle compositions. The isoflavone nanoparticle compositions contain isoflavone in the form of nanoparticles and preferably a carrier. In the topical compositions recrystallization of the isoflavone to bigger particles is avoided.Type: ApplicationFiled: January 31, 2006Publication date: December 18, 2008Inventors: Raphael Beumer, Chyi-Cheng Chen, Heinz Gutzwiller, Philippe Emmanuel Maillan, Markus Nowotny, Bernd Schlegel, Juergen Vollhardt
-
Publication number: 20080311136Abstract: This invention relates to compounds comprising one or more therapeutic and/or diagnostic moieties and one or more functional moieties linked together via one or more triazole-containing linkers and to their intermediates and methods of their preparation. The triazole-containing linker may optionally contain one or more conditionally-cleavable or conditionally-transformable moieties and one or more spacer systems in between said moiety/moieties and the one or more therapeutic and/or diagnostic moieties.Type: ApplicationFiled: August 3, 2006Publication date: December 18, 2008Inventors: Patrick Henry Beusker, Franciscus Marinus Hendrikus De Groot
-
Publication number: 20080305989Abstract: Transdermal delivery peptides for the treatment of skin diseases and/or facilitation or enhancement of transdermal delivery of pharmaceutically active agents are provided. Compositions comprising the transdermal delivery peptides and methods of therapeutic use, including the improvement of transdermal delivery of drugs or other pharmaceutically active agents, are also disclosed. Nucleic acids, expression vectors, and methods of their use, which encode the transdermal delivery peptides are disclosed. Methods are also provided for in vivo phage display for identifying further peptides with enhanced transdermal delivery capability.Type: ApplicationFiled: September 14, 2006Publication date: December 11, 2008Inventors: Long-Ping Wen, Yongping Chen, Yuanyuan Shen, Xin Guo, Weiping Wang, Brian Zhang
-
Publication number: 20080293617Abstract: The present invention provides compositions for an implantable putty material for delivery of active compounds to a patient. More specifically, the present invention provides a material having a pH of between about 3 and 6 and possessing putty-like physical properties, wherein the composition of the material includes collagen and water. The present invention also provides a method for using the implantable putty material.Type: ApplicationFiled: July 25, 2008Publication date: November 27, 2008Inventors: James J. Benedict, Christopher J. Damien
-
Publication number: 20080287551Abstract: The present invention discloses the use of a lycopene coated with a water non-soluble thin film comprising amphiphilic protein polymer for coloring with red color, foods, pharmaceuticals or cosmetics having fat and/or oil contents higher than 5%. The invention further discloses a process for the preparation of stable lycopene formulation comprising (a) treating an isolated protein to form a protein in a molecular form; (b) dispersing lycopene in an aqueous solution comprising an isolated protein in a molecular form; (c) grinding said dispersion to form lycopene particle size of 1 to 10 ?m forming an homogenized mixture comprising fine particles; and optionally (d) drying the homogenized mixture.Type: ApplicationFiled: July 29, 2008Publication date: November 20, 2008Applicant: LYCORED NATURAL PRODUCTS INDUSTRIES LTD.Inventors: Nissim Garti, Morris Zelkha, Tanya Sedlov
-
Publication number: 20080286364Abstract: An object of the present invention is to provide an external dermatologic preparation which comprises nanoparticles consisting of proteins that can exhibit desirable effects via regulation of particle diameters. The present invention provides an external dermatologic preparation which comprises protein nanoparticles containing an active ingredient and having an average particle size of 200 to 500 nm.Type: ApplicationFiled: May 15, 2008Publication date: November 20, 2008Applicant: FUJIFILM CorporationInventors: Kazutaka OGIWARA, Makiko Aimi, Shouji Ooya
-
Publication number: 20080279918Abstract: It is intended to efficiently inject into a target cell, a substance charged within a liposome. The present inventors have found that connexin synthesized within a liposome is introduced as connexon having a gap junction function into the liposome membrane. Specifically, the liposome according to the present invention is a liposome in which connexon composed of connexin synthesized by an in-vitro protein synthesis system is incorporated in a state of having a gap junction function.Type: ApplicationFiled: November 2, 2005Publication date: November 13, 2008Applicants: National University Corporation Tokyo Medical and Dental University, Dai Nippon Printing Co., Ltd.Inventors: Ikuo Morita, Kazunari Akiyoshi, Shinichiro Nomura